• 1
    Schafer AI. Approach to bleeding. In: LoscalzoJ, SchaferAI, eds. Thrombosis and Hemorrhage, Chapter 23. Cambridge, MA: Blackwell Scientific Publications, 1994: 40722.
  • 2
    Quiroga T, Pérez M, Rodríguez S, Muñoz B, Aranda E, Morales M, Verdugo P, Pereira J, Mezzano D. Skin and mucous membrane hemorrhages: clinical assessment, study sequence and relative frequency of hereditary diseases of the hemostasis in a Chilean population. Rev Med Chil 1997; 125: 40918.
  • 3
    Posan E, McBane RD, Grill DE, Motsko CL, Nichols WL. Comparison of PFA-100 testing and bleeding time for detecting platelet hypofunction and von Willebrand disease in clinical practice. Thromb Haemost 2003; 90: 48390.
  • 4
    Burns ER, Lawrence C. Bleeding time. A guide to its diagnostic and clinical utility. Arch Pathol Lab Med 1989; 113: 121924.
  • 5
    Rodgers RPC, Levin J. A critical reappraisal of the bleeding time. Sem Thromb Haemost 1990; 16: 120.
  • 6
    Lind SE. The bleeding time does not predict clinical bleeding. Blood 1991; 77: 254752.
  • 7
    Triplett DA. The bleeding time. Neither pariah or panacea. Arch Pathol Lab Med 1989; 113: 12078.
  • 8
    Fressinaud E, Veyradier A, Truchaud F, Martin I, Boyer-Neumann C, Trossaert M, Meyer D. Screening for von Willebrand disease with a new analyzer using high shear stress: a study of 60 cases. Blood 1998; 91: 132531.
  • 9
    Cattaneo M, Federici AB, Lecchi A, Agati B, Lombardi R, Stabile F, Bucciarelli P. Evaluation of the PFA-100® system in the diagnosis and therapeutic monitoring of patients with von Willebrand disease. Thromb Haemost 1999; 82: 359.
  • 10
    Dean JA, Blanchette VS, Carcao MD, Stain AM, Sparling CR, Siekmann J, Turecek PL, Lillicrap D, Rand ML. Von Willebrand disease in a pediatric-based population—comparison of type 1 diagnostic criteria and use of the PFA-100® and a von Willebrand factor/collagen binding assay. Thromb Haemost 2000; 84: 4019.
  • 11
    Schlammadinger A, Kerényi A, Muszbek L, Boda Z. Comparison of the O'Brien filter test and the PFA-100 platelet analyzer in the laboratory diagnosis of von Willebrand's disease. Thromb Haemost 2000; 84: 8892.
  • 12
    Favaloro EJ, Kershaw G, Bukuya M, Hertzberg M, Koutts J. Laboratory diagnosis of von Willebrand disorder (VWD) and monitoring of DDAVP therapy: efficacy of the PFA-100® and VWF. CBA as combined diagnostic strategies. Haemophilia 2001; 7: 1809.
  • 13
    Favaloro EJ. Clinical application of the PFA-100®. Curr Opin Hematol 2002; 9: 40715.
  • 14
    Cattaneo M, Lecchi A, Agati B, Lombardi R, Zighetti ML. Evaluation of platelet function with the PFA-100® system in patients with congenital defects of platelet secretion. Thromb Res 1999; 96: 2137.
  • 15
    Kerényi A, Schlammadinger A, Ajzner E, Szegedi I, Kiss C, Pap Z, Boda Z, Muszbek L. Comparison of PFA-100 closure time and template bleeding time of patients with inherited disorders causing defective platelet function. Thromb Res 1999; 96: 48792.
  • 16
    Cattaneo M. Inherited platelet-based bleeding disorders. J Thromb Haemost 2003; 1: 162836.
  • 17
    Langdell RD, Wagner RH, Brinkhous KM. Effect of antihemophilic factor on one-stage clotting tests. J Lab Clin Med 1953; 41: 63747.
  • 18
    Allain JP, Cooper HA, Wagner RH, Brinkhous KM. Platelets fixed with paraformaldehyde: a new reagent for assay of von Willebrand factor and platelet aggregating factor. J Lab Clin Med 1975; 85: 31828.
  • 19
    Siekmann J, Turecek PL, Schwarz HP. The determination of von Willebrand factor activity by collagen binding assay. Haemophilia 1998; 4 (Suppl. 3): 1524.
  • 20
    Budde U, Schneppenheim R, Plendl H, Dent J, Ruggeri ZM, Zimmerman TS. Luminographic detection of von Willebrand factor multimers in agarose gels and on nitrocellulose membranes. Thromb Haemost 1990; 63: 3125.
  • 21
    Quiroga T, Tagle R, Pereira J, Mezzano D. Sex-related difference in plasma von Willebrand factor (VWF:Ag and VWF:RiCof) levels in adolescents. Thromb Haemost 1994; 71: 8001.
  • 22
    Mezzano D, Tagle R, Panes O, Pérez M, Downey P, Muñoz B, Aranda E, Barja P, Thambo S, González F, Mezzano S, Pereira J. Hemostatic disorder of uremia: the platelet defect, main determinant of the prolonged bleeding time, is correlated with indices of activation of coagulation and fibrinolysis. Thromb Haemost 1996; 76: 31221.
  • 23
    Kumar AM, Kumar M, Deepika K, Fernandez JB, Eisdorfer C. A modified HPLC technique for simultaneous measurement of 5-hydroxytryptamine and 5-hydroxyindoleacetic acid in cerebrospinal fluid, platelet and plasma.Life Sci 1990; 47: 17519.
  • 24
    Favaloro EJ. Utility of the PFA-100® for assessing bleeding disorders and monitoring therapy: a review of analytical variables, benefits and limitations. Haemophilia 2001; 7: 1709.
  • 25
    Nosek-Cenkowska B, Cheang MS, Pizzi NJ, Israels ED, Gerrard JM. Bleeding/bruising symtomatology in children with and without bleeding disorders. Thromb Haemost 1991; 65: 23741.
  • 26
    Mauser Bunschoten EP, Van Houwelingen JC, Sjamsoedin Visser EJM, Van Dijken PJ, Kok AJ, Sixma JJ. Bleeding symptoms in carriers of haemophilia A and B. Thromb Haemost 1988; 59: 34952.
  • 27
    Wuillemin WA, Gasser KM, Zeerleder SS, Lämmle B. Evaluation of a platelet function analyzer (PFA-100®) in patients with a bleeding tendency. Swiss Med Wkly 2002; 132: 4438.
  • 28
    Gerrard JM, Duta E, Nosek-Cenkowska B, Singhroy S, Cheang M, Kobrinsky NL. A role for prostacyclin in bruising symptomatology. Pediatrics 1992; 90: 336.
  • 29
    Simon DI, Stamler JS, Loh E, Loscalzo J, Francis SA, Creager MA. Effects of nitric oxide synthase inhibition on bleeding time in humans. J Cardiovasc Pharmacol 1995; 26: 33942.
  • 30
    Ubatuba FB, Moncada S, Vane JR. The effect of prostacyclin (PGI2) on platelet behaviour. Thrombus formation in vivo and bleeding time. Thromb Haemost 1979; 23: 42535.